In the Drug Evaluation ‘Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: A review of the literature’ by Mancini M et al. published in Expert Opinion on Pharmacotherapy (Expert Opin. Pharmacother. (2010) 11(7):1167-1181), the second to last paragraph in the section on Clinical studies and indications for use (Section 4) should have read as follows:
Based on the results of four large, placebo-controlled trials of duloxetine on patients with GAD, the FDA approved the use of duloxetine for the treatment of GAD in February 2007 [25]. The approval by the EMEA for this indication followed in June 2008 at doses of 30 -- 120 mg/day [27].
The authors and publishers apologise for any inconvenience caused.